Soiken Holdings Inc.
Stock Price Chart
2026/09/25 17:58 UpdatedPrice Trend
2026/09/25 17:58 UpdatedPrice & Trading Details
2026/09/25 17:58 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Dividend History 1Years Growth
Updated 2026/09/27| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥10 | +100.0% |
| 2025 | ¥5 | 0.0% |
| 2023 | ¥5 | 0.0% |
| 2022 | ¥5 | 0.0% |
| 2021 | ¥5 | - |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥9,348M | ¥8,080M | ¥5,158M | ¥4,849M |
| Gross Profit | ¥4,260M | ¥3,716M | ¥2,482M | ¥2,410M |
| Operating Income | ¥1,209M | ¥726M | -¥610M | -¥138M |
| Pretax Income | ¥1,209M | ¥726M | -¥610M | -¥138M |
| Net Income | ¥810M | ¥452M | -¥662M | -¥211M |
| EPS | ¥30.95 | ¥17.27 | - | -¥8.05 |
| Operating Margin | 12.93% | 8.98% | -11.83% | -2.84% |
| Balance Sheet | ||||
| Total Assets | ¥8,490M | ¥8,240M | ¥6,946M | ¥6,813M |
| Total Equity | ¥6,648M | ¥6,969M | ¥6,233M | ¥6,022M |
| Total Liabilities | ¥1,842M | ¥1,271M | ¥713M | ¥791M |
| Cash | ¥6,017M | ¥5,946M | ¥4,790M | ¥4,958M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 78.31% | 84.57% | 89.73% | 88.39% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥2,136M | -¥102M | -¥881M | ¥558M |
| Investing CF | -¥245M | ¥160M | -¥14M | -¥389M |
| Financing CF | -¥130M | -¥130M | -¥261M | -¥0M |
| Free CF | ¥2,091M | -¥141M | -¥895M | ¥521M |
| Efficiency | ||||
| ROE | 12.18% | 6.48% | -10.62% | -3.50% |
| ROA | 9.54% | 5.48% | -9.53% | -3.09% |
Latest IR Information
-
Notice of the conclusion of a joint research framework agreement for new functional materials with the China-based Sichuan Colun Pharmaceutical Group
Entered into a joint research framework agreement with the China-based Sichuan Colun Pharmaceutical Group. Aiming to research, develop, and commercialize functional materials in the Japanese market; domestic clinical studies and functional assessments to be conducted by Soiken Holdings, with Sino-Japanese...
Read more -
Notice Regarding Executive Changes
A resolution is planned regarding executive changes including appointments and retirements. The six current directors’ terms expire at the conclusion of the 32nd annual general meeting; founder Osamu Kajimoto will retire but will continue to be involved as an adviser....
Read more -
Notice Regarding the Introduction of a Restricted Stock Unit System
A restricted stock unit compensation system is being newly established. A monetary claim will be granted to eligible directors as consideration in kind, with ordinary shares issued or disposed. The total amount cap is 3,000 million yen per year, and...
Read more -
Financial Summary for the Fiscal Year Ending June 2026 (Japanese GAAP) (Consolidated)
For the fiscal year ending June 2026, consolidated net sales were 387.1 million yen, operating income was 275 million yen, and net income attributable to owners of the parent was 212 million yen. Full-year guidance is net sales of 3,270...
Read more -
Notice regarding the differences between the consolidated full-year earnings forecast for the year ending June 2026 and actual results
Full-year consolidated earnings forecast for the year ending June 2026 was raised. Revenue from 3,860 million yen to 3,871 million yen; operating income from -180 million yen to 275 million yen; and other segment adjustments. Profitability improvements are progressing in...
Read more
Latest News (5 items)
Company Information
About
Soiken Holdings Inc. engages in the development of biomarkers in Japan and internationally. The company is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.
